PROK 1.97 ProKidney Corp.
| Range: | 1.12-4.44 | Vol Avg: | 702639 | Last Div: | 0 | Changes: | 0.13 |
| Beta: | 1.28 | Cap: | 0.53B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed Jun 30 2021 | Empoloyees: | 163 | ||
| CUSIP: | CIK: | 0001850270 | ISIN: | KYG7S53R1049 | Country: | US | |
| CEO: | Dr. Bruce Culleton M.D. | Website: | https://www.prokidney.com | ||||
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Stock Details
PROK 3
ProKidney price target lowered to $3 from $4 at BofA
Jason Gerberry·Wed Sep 04 2024
Bank of America Securities
PROK 5
BTIG Reiterates Buy Rating on ProKidney Corp. (PROK)
Justin Zelin·Tue Sep 03 2024
BTIG
PROK 6
ProKidney Corp. (PROK) PT Lowered to $6 at Jefferies
Kelly Shi·Mon Jun 10 2024
Jefferies
PROK 6
BTIG Reiterates Buy Rating on ProKidney Corp. (PROK)
Justin Zelin·Tue May 28 2024
BTIG
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow